alexa Thyroid Autoimmune Diseases And Graves Ophthalmopathy: New Therapeutics
ISSN: 2161-1017

Endocrinology & Metabolic Syndrome
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

6th International Conference on Diabetes and Endocrinology
December 05-07, 2016 Dallas, USA

Alessandro Antonelli
University of Pisa, School of Medicine, Italy
Keynote: Endocrinol Metab Syndr
DOI: 10.4172/2161-1017.C1.016
The C-X-C chemokine receptor (CXCR)3 and its IFN-γ dependent chemokines (CXCL9, CXCL10, CXCL11) play an important role in the pathogenesis of autoimmune thyroiditis (AT), Graves’ disease (GD) and Graves’ Ophthalmopathy (GO). Thyrocytes, orbital fibroblasts and preadipocytes, under the influence of interferon (IFN)γ, secrete the aforementioned chemokines. Th1 lymphocytes recruitment in tissue increases IFNγ production, enhancing the IFNγ-inducible chemokine tissue secretion, and leading to the beginning and perpetuation of the autoimmune process. High levels of circulating IFNγ- inducible chemokines have been reported in patients with AT (especially in the presence of hypothyroidism), and in GD and GO patients particularly in the active phase. Peroxisome proliferator-activated receptor (PPAR)γ or -α agonists have a modulatory role on CXCR3 chemokines in AT, GD and GO. An immuno-modulatory effect on CXCR3 chemokines in GD is exerted by methimazole and corticosteroids, too. Further studies investigate the use of new molecules acting as antagonists of CXCR3, or blocking CXCL10, in HT, GD and GO. Recently novel agents targeting various agents involved in the pathogenesis of GO have been proposed as an alternative to corticosteroids. A randomized trial with Rituximab suggests good efficacy with a relative well tolerated profile in patients with active GO. Anyway, discordant results have been reported. Hoping results in GO have been given by small antagonists of thyroid stimulating hormone receptor molecules (interacting with the receptor on thyrocytes and fibroblasts), the anti-IGF-1 receptor antibody teprotumumab, and tocilizumab (an anti-soluble interleukin-6 receptor). Randomized and controlled studies are needed to generalize these intriguing results.

Alessandro Antonelli (Associate Professor, MD) has completed his degree in Medicine, cum laude, in 1982, Specialization in Endocrinology in 1985, Specialization in Occupational Health in 1987, and Specialization in Oncology in 1992, at the University of Pisa, Pisa, Italy. He is now working as Associate Professor in the Department of Clinical and Experimental Medicine at the University of Pisa. His researches have been published in more than 280 articles on International journals (Impact Factor > 920, H-I=54). He serves as an Editorial Board Member and is Referee and Reviewer of many scientific international journals.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version